AR039383A1 - Derivados del tropano utiles en terapia - Google Patents

Derivados del tropano utiles en terapia

Info

Publication number
AR039383A1
AR039383A1 ARP030101205A ARP030101205A AR039383A1 AR 039383 A1 AR039383 A1 AR 039383A1 AR P030101205 A ARP030101205 A AR P030101205A AR P030101205 A ARP030101205 A AR P030101205A AR 039383 A1 AR039383 A1 AR 039383A1
Authority
AR
Argentina
Prior art keywords
alkyl
conr6r7
nr6r7
substituted
atoms
Prior art date
Application number
ARP030101205A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0208071.1A external-priority patent/GB0208071D0/en
Priority claimed from GB0301575A external-priority patent/GB0301575D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR039383A1 publication Critical patent/AR039383A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)

Abstract

Los compuestos de la presente son moduladores, especialmente antagonistas, de la actividad de los receptores CCR5 de quimioquinas. Los moduladores del receptor CCR5 pueden ser útiles para el tratamiento de diversas enfermedades inflamatorias y situaciones con inflamaciones, y para el tratamiento de la infección por el HIV-1 y retrovirus genéticamente relacionados. Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1) o una de sus sales, solvatos o derivados farmacéuticamente aceptables, en el que: X e Y se seleccionan entre CH2 y NR4 de forma de que X e Y uno de ellos es CH2 y el otro es NR4; R1 y R4 son independientemente R5; COR5; CO2R5; CONR6R7; SO2R5; o (alquilen C1-6)fenilo, en el que el fenilo está sustituido con de 0 a 3 átomos o grupos seleccionados entre alquilo C1-6, alquil(C1-6)-carbonilo, alcoxi C1-6, alcoxi(C1-6)-carbonilo, halógeno, CF3, OH, CN, NR6R7,CO2R7 ó CONR6R7; R2 es un fenilo sustituido con de 0 a 3 átomos o grupos seleccionados entre alquilo C1-6, alquil(C1-6)-carbonilo, alcoxi C1-6, alcoxi(C1-6)-carbonilo, halógeno, CF3, OH, CN, NR6R7, CO2R7 ó CONR6R7; R3 es un alquilo C1-4 sustituido con de 0 a 3 átomos de flúor; R5 es un alquilo C1-6; alquenilo C2-6; alquinilo C2-6; cicloalquilo C3-7; un heterociclo aromático de 5 ó 6 miembros, o un heterociclo saturado de 4 a 7 miembros; en el que dichos alquilo, alquenilo, alquinilo y cicloalquilo están sustituidos con de 0 a 3 átomos o grupos seleccionados entre oxo, halógeno, CF3, OR7, CN, NR6R7, COR7, CO2R7 ó CONR6R7; en el que dichos heterociclos contienen de uno a tres heteroátomos seleccionados entre N, O ó S; y en el que dichos heterociclos están sustituidos con de 0 a 3 átomos o grupos seleccionados entre alquilo C1-6, alquilo(C1-6)-carbonilo, alcoxi C1-6, alcoxi(C1-6)-carbonilo, halógeno, CF3, OH, CN, NR6R7, COR7, CO2R7 ó CONR6R7; R6 es H ó R5; R7 es H o un alquilo C1-6; o, cuando R6 y R7 están ambos unidos al mismo átomo de N, NR6R7 puede representar también un heterociclo de 5 a 7 miembros, saturado, parcialmente insaturado o aromático, que contiene de 0 a 2 heteroátomos adicionales seleccionados entre O, N ó S.
ARP030101205A 2002-04-08 2003-04-07 Derivados del tropano utiles en terapia AR039383A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208071.1A GB0208071D0 (en) 2002-04-08 2002-04-08 Tropane derivatives useful in therapy
GB0301575A GB0301575D0 (en) 2003-01-23 2003-01-23 Tropane derivatives useful in therapy

Publications (1)

Publication Number Publication Date
AR039383A1 true AR039383A1 (es) 2005-02-16

Family

ID=28793308

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101205A AR039383A1 (es) 2002-04-08 2003-04-07 Derivados del tropano utiles en terapia

Country Status (41)

Country Link
EP (1) EP1492789B1 (es)
JP (2) JP3793200B2 (es)
KR (1) KR100734685B1 (es)
CN (1) CN1324025C (es)
AP (1) AP1789A (es)
AR (1) AR039383A1 (es)
AT (1) ATE328882T1 (es)
AU (1) AU2003214503B2 (es)
BR (1) BR0309118A (es)
CA (1) CA2481482C (es)
CR (1) CR7514A (es)
CU (1) CU23282A3 (es)
CY (1) CY1106114T1 (es)
DE (1) DE60305903T2 (es)
DK (1) DK1492789T3 (es)
DO (1) DOP2003000624A (es)
EA (1) EA007590B1 (es)
ES (1) ES2263960T3 (es)
GE (1) GEP20074210B (es)
HK (1) HK1076102A1 (es)
HN (1) HN2003000114A (es)
HR (1) HRP20040940A2 (es)
IL (1) IL164261A0 (es)
IS (1) IS2577B (es)
MA (1) MA27190A1 (es)
MX (1) MXPA04009220A (es)
MY (1) MY134223A (es)
NI (1) NI200300053A (es)
NO (1) NO329674B1 (es)
NZ (1) NZ535452A (es)
OA (1) OA12798A (es)
PA (1) PA8570801A1 (es)
PE (1) PE20040082A1 (es)
PL (1) PL372968A1 (es)
PT (1) PT1492789E (es)
RS (1) RS51550B (es)
SI (1) SI1492789T1 (es)
TN (1) TNSN04194A1 (es)
TW (1) TWI280130B (es)
UY (1) UY27752A1 (es)
WO (1) WO2003084954A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3793200B2 (ja) * 2002-04-08 2006-07-05 ファイザー・インク Ｃｃｒ５モジュレータとしてのトロパン誘導体
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
AP2174A (en) * 2003-10-03 2010-11-20 Pfizer Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7751601B2 (en) 2004-10-04 2010-07-06 Validity Sensors, Inc. Fingerprint sensing assemblies and methods of making
US8131026B2 (en) 2004-04-16 2012-03-06 Validity Sensors, Inc. Method and apparatus for fingerprint image reconstruction
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
JP5194105B2 (ja) 2007-04-13 2013-05-08 ドン ファ ファーマシューティカル カンパニー リミテッド １−シクロプロピル−６−フルオロ−７−（８−メトキシイミノ−２，６−ジアザ−スピロ［３．４］オクト−６−イル）−４−オキソ−１，４−ジヒドロ−［１，８］ナフチリジン−３−カルボン酸のアスパラギンサン酸塩、その製造方法、およびそれを含む抗菌用薬学組成物
US7947710B2 (en) 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CN101712679B (zh) 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
CA2778206A1 (en) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
JP5731538B2 (ja) 2009-12-23 2015-06-10 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｃｒｔｈ２モジュレーター
WO2011121558A1 (en) 2010-04-02 2011-10-06 Phivco-1 Llc Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN106977511B (zh) * 2011-12-19 2019-04-12 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321749D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
MA42954A (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals Europe Ltd Potentialisateurs cftr deutérés
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
US11708331B2 (en) 2017-12-01 2023-07-25 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2019183133A1 (en) 2018-03-19 2019-09-26 Emory University Pan-Tropic Entry Inhibitors
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド 重水素化されたｃｆｔｒ増強物質
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
WO2001080106A1 (fr) * 2000-04-19 2001-10-25 Satoshi Yamazaki Procede de diffusion d'outil publicitaire et support magnetique pour le logiciel
DE60102233T2 (de) * 2000-05-26 2005-01-27 Pfizer Inc. Triazolyltropanderivate als ccr5-modulatoren
JP3793200B2 (ja) * 2002-04-08 2006-07-05 ファイザー・インク Ｃｃｒ５モジュレータとしてのトロパン誘導体

Also Published As

Publication number Publication date
DK1492789T3 (da) 2006-09-11
KR100734685B1 (ko) 2007-07-02
NI200300053A (es) 2005-11-01
CA2481482C (en) 2009-11-10
JP2005532285A (ja) 2005-10-27
NZ535452A (en) 2006-11-30
HN2003000114A (es) 2004-05-05
PE20040082A1 (es) 2004-03-20
CR7514A (es) 2004-11-08
AU2003214503A1 (en) 2003-10-20
HRP20040940A2 (en) 2005-04-30
RS51550B (en) 2011-06-30
HK1076102A1 (en) 2006-01-06
PT1492789E (pt) 2006-09-29
JP4571078B2 (ja) 2010-10-27
AU2003214503B2 (en) 2008-08-07
DE60305903T2 (de) 2007-03-08
WO2003084954A1 (en) 2003-10-16
IL164261A0 (en) 2005-12-18
ATE328882T1 (de) 2006-06-15
BR0309118A (pt) 2005-02-01
AP1789A (en) 2007-10-05
AP2004003147A0 (en) 2004-09-30
CY1106114T1 (el) 2011-06-08
NO329674B1 (no) 2010-11-29
ES2263960T3 (es) 2006-12-16
SI1492789T1 (sl) 2006-10-31
JP2006182784A (ja) 2006-07-13
MY134223A (en) 2007-11-30
CN1646526A (zh) 2005-07-27
MXPA04009220A (es) 2005-09-30
GEP20074210B (en) 2007-10-10
KR20040099420A (ko) 2004-11-26
NO20044615L (no) 2004-10-26
TWI280130B (en) 2007-05-01
EP1492789A1 (en) 2005-01-05
TW200403242A (en) 2004-03-01
RS88804A (en) 2006-12-15
UY27752A1 (es) 2003-11-28
TNSN04194A1 (fr) 2007-03-12
DE60305903D1 (de) 2006-07-20
OA12798A (en) 2006-07-10
JP3793200B2 (ja) 2006-07-05
EP1492789B1 (en) 2006-06-07
IS2577B (is) 2010-02-15
CU23282A3 (es) 2008-06-30
CN1324025C (zh) 2007-07-04
PL372968A1 (en) 2005-08-08
CA2481482A1 (en) 2003-10-16
EA200401167A1 (ru) 2005-04-28
DOP2003000624A (es) 2003-10-15
IS7453A (is) 2004-09-16
MA27190A1 (fr) 2005-01-03
EA007590B1 (ru) 2006-12-29
PA8570801A1 (es) 2004-11-26

Similar Documents

Publication Publication Date Title
AR039383A1 (es) Derivados del tropano utiles en terapia
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
CO4810382A1 (es) Compuestos de indol agentes anti-inflamatorios/analgesicos
AR031680A1 (es) Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
AR049647A1 (es) Cis-imidazolinas
AR042437A1 (es) Derivados de fluoroglicosidos heterociclicos, medicamentos que los contienen y usos
AR051997A1 (es) Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
UY26143A1 (es) Derivados heterocíclicos útiles como agentes anticancerosos
AR035631A1 (es) Compuestos quimicos
AR037983A1 (es) Derivados de pirido [2,1-a] isoquinolina
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
AR005876A1 (es) Esteres azabiciclicos de acidos carbamicos utiles en terapia, composicion farmaceutica que incluye a dichos esteres, uso de dichos esteres, metodos parael tratamiento o profilaxis de varios desordenes, enfermedades y adicciones, procedimiento para la preparacion de dichos esteres, intermediarios utilizados
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
AR040352A1 (es) Derivados de indolinfenilsulfonamida
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
PE20040168A1 (es) Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR050274A1 (es) Derivados triciclicos del indeno-pirrol como moduladores de la serotonina
AR045856A1 (es) Derivados de tropano sustituidos con imidazopiridinas,procedimiento de preparacion,composiciones farmaceuticas que los contienen y usos,
PE20220578A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
AR045949A1 (es) Derivados de piridina, inhibidores de urotensina ii
AR006719A1 (es) Derivados de bencilamina y formulacion farmaceutica que comprende a uno de dichos derivados.
AR079885A1 (es) Derivados de oxazolo[5,4-d]pirimidina 2,5-sustituidos utiles para el tratamiento del sindrome del pie diabetico(dfs), composiciones farmaceuticas que los contienen y proceso para prepararlos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure